ArticleOncotarget2017

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF

Zeus A Antonello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.